In Vivo Effectiveness of a High-Yield Factor VIII Concentrate Prepared in a Blood Bank

Publisher Website
Google Scholar
Abstract
1YOPHILIZED factor VIII concentrates have beJ come the treatment of choice for factor VIII-deficient patients with hemophilia. The cost of such treatment is high, primarily because under normal conditions of collection and preparation, factor VIII procoagulant activity (VIIIC, sec Table 1 for terms and definitions1) is unstable and as much as 80 per cent of the activity is lost during the purification procedure. Recently, we have reported that factor VIIIC activity is stabilized when blood is collected into heparin rather than citrate anticoagulant, and we have shown that the cryoprecipitates obtained from heparinized blood contain 80 per cent of the VIIIC . . .